SEEL — Seelos Therapeutics Share Price
0.000.00%
Last trade - 00:00- $6.32m
- $17.54m
- $2.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -2253.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.38 | n/a | n/a | n/a | 2.2 | n/a | 28.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Directors
- Raj Mehra CHM (61)
- Michael Golembiewski CFO (50)
- Anthony Marciano OTH
- Margaret Dalesandro DRC (75)
- Richard Pascoe DRC (57)
- Brian Lian IND (55)
- Daniel O'Connor IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 20th, 1987
- Public Since
- October 27th, 1993
- No. of Shareholders
- 104
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 13,680,576
- Address
- 300 PARK AVENUE, 2ND FLOOR, NEW YORK, 10022
- Web
- https://seelostherapeutics.com/
- Phone
- +1 6462932100
- Contact
- Anthony Marciano
- Auditors
- KPMG LLP
Upcoming Events for SEEL
Seelos Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Seelos Therapeutics Inc Earnings Release
Similar to SEEL
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Seelos Therapeutics share price?
As of Today at 19:19 UTC, shares in Seelos Therapeutics are trading at $0.46. This share price information is delayed by 15 minutes.
How has the Seelos Therapeutics share price performed this year?
Shares in Seelos Therapeutics last closed at $0.46 and the price had moved by -98.1% over the past 365 days. In terms of relative price strength the Seelos Therapeutics share price has underperformed the S&P500 Index by -98.46% over the past year.
What are the analyst and broker recommendations for Seelos Therapeutics?
The overall consensus recommendation for Seelos Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Seelos Therapeutics dividend yield?
Seelos Therapeutics does not currently pay a dividend.
Does Seelos Therapeutics pay a dividend?
Seelos Therapeutics does not currently pay a dividend.
When does Seelos Therapeutics next pay dividends?
Seelos Therapeutics does not currently pay a dividend.
How do I buy Seelos Therapeutics shares?
To buy shares in Seelos Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Seelos Therapeutics?
As of the previous close price of $0.46, shares in Seelos Therapeutics had a market capitalisation of $6.32m.
Where are Seelos Therapeutics shares listed?
Here are the trading details for Seelos Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SEEL
What kind of share is Seelos Therapeutics?
Based on an overall assessment of its quality, value and momentum Seelos Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Seelos Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Seelos Therapeutics is $120.00. That is 25868.41% above the last closing price of $0.46.
Analysts covering Seelos Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.09 for the next financial year.
What is the trend in the Seelos Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Seelos Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -92.82%.
As of the last closing price of $0.46, shares in Seelos Therapeutics were trading -96.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Seelos Therapeutics PE Ratio?
The Seelos Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Seelos Therapeutics?
Seelos Therapeutics' management team is headed by:
- Raj Mehra - CHM
- Michael Golembiewski - CFO
- Anthony Marciano - OTH
- Margaret Dalesandro - DRC
- Richard Pascoe - DRC
- Brian Lian - IND
- Daniel O'Connor - IND